Description
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, Heparin Plasma, Serum,
Reacts with:Human,
Assay type:Indirect,
Assay Platform:Microplate
Product details:
Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) ab108730 is an indirect ELISA for the qualitative detection of Human Anti-Epstein Barr virus IgG (EBV-VCA) antibodies in serum, plasma.
How the assay works:
A 96-well plate has been precoated with Epstein Barr virus antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgG conjugate is added to the wells, which binds to the immobilized Epstein Barr virus-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Epstein Barr virus IgG sample captured in plate.
Assay Specificity
Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details
Human Anti-Epstein Barr virus IgG ELISA Kit (EBV-VCA) ab108730 protocol summary
1. Add samples and controls to wells used. Incubate at 37°C
2. Wash each well and add prepared labeled HRP-Conjugate. Incubate at room temperature
3. After washing, add TMB substrate solution to each well. Incubate at room temperature
4. Add Stop Solution to each well. Read immediately.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Epstein-Barr Virus (EBV) VCA IgG antibodies are molecular indicators developed by the immune system in response to the structural proteins of the viral capsid of EBV particularly the viral capsid antigen (VCA). These proteins facilitate the formation of the viral shell. VCA IgG antibodies typically have a mass of approximately 150 kDa and are expressed during the acute and convalescent phases of EBV infection. The presence of these antibodies can often be found in serum samples indicating past infection since VCA IgG appears late and persists for a lifetime.
Biological function summary
EBV VCA IgG antibodies participate in the immune surveillance mechanism against the EBV. They belong to the immunoglobulin class and indicate an adaptive immune response helping to neutralize viral particles and prevent EBV from causing further infection. These antibodies do not work as part of a larger complex but operate independently to tag viral particles for destruction by immune cells. The detection of these antibodies therefore serves as a marker for prior EBV exposure and helps assess the immune status of individuals.
Pathways
EBV VCA IgG antibodies primarily influence immune response pathways particularly the humoral immune response. They do not directly participate in signaling pathways but result from the activity of B cells within the adaptive immune system as they recognize EBV VCA. B cell differentiation and activation are closely related and proteins like CD20 and CD19 are important in this process as they support the proliferation and development of antibody-producing cells.
EBV VCA IgG antibodies relate directly to infectious mononucleosis a condition commonly caused by EBV. A high level of these antibodies indicates a past or ongoing EBV infection and can aid in the diagnosis of mononucleosis. Furthermore chronic active EBV infection can be represented by persistent high titer levels of EBV VCA IgG. It is essential to acknowledge the connection of these antibodies to EBV-associated cancers such as Burkitt's lymphoma where EBV contributes to the oncogenic process along with other proteins like LMP1 (latent membrane protein 1) which play significant roles in tumorigenesis.
